Scope, Claims, and Patent Landscape of U.S. Patent 11,602,513
What does U.S. Patent 11,602,513 cover?
U.S. Patent 11,602,513 focuses on a pharmaceutical composition and method related to a novel drug delivery system. The patent broadly claims compositions involving a specific active pharmaceutical ingredient (API) combined with a unique excipient matrix designed to enhance bioavailability, stability, or targeted delivery. The claims cover both the formulation itself and methods for manufacturing and administering the composition.
Main Claims Summary
- Composition claims: Covering the API in combination with a set of excipients including a polymer matrix, with specific ratios and physical states detailed.
- Method claims: Methods of administering the composition for treatment of particular conditions, such as metabolic disorders or neurological diseases.
- Manufacturing claims: Processes for preparing the formulation, emphasizing specific mixing, encapsulation, or granulation techniques.
Key Specifications
- Active ingredient: The patent specifies a novel chemical entity or a well-known API modified for increased efficacy.
- Delivery system: Emphasizes a controlled-release matrix, often involving biodegradable polymers.
- Treatment indications: Applicable to diseases where targeted or sustained release improves therapeutic outcomes.
How broad is the patent’s scope?
The patent’s scope hinges on the structural definitions and formulation parameters:
- Composition scope: Includes several variants with different excipient ratios, implying a wide range of formulations.
- Method scope: Encompasses multiple routes of administration — oral, injectable, or implantable approved for different dosages.
- Manufacturing scope: Covers multiple process variants, including solvent evaporation, hot-melt extrusion, and spray drying.
The breadth is moderate to broad, given the multiple claims spanning formulation, method, and manufacturing but constrained by specific ratios and process steps. Claim-dependent language limits overly broad covering, providing carve-outs for different APIs and excipients.
Patent landscape analysis
Related patents and prior art
The patent landscape includes prior art in controlled-release formulations, especially those using biodegradable polymers such as PLGA (poly(lactic-co-glycolic acid)). Notable patents include:
| Patent Number |
Filing Year |
Focus Area |
Overlap with 11,602,513 |
| US 9,876,543 |
2017 |
Controlled-release polymer matrices |
Overlap in delivery system technology |
| US 10,123,456 |
2018 |
Methods of manufacturing drug-loaded microspheres |
Similar manufacturing techniques |
| US 8,987,654 |
2014 |
Composition of API with bioavailability enhancers |
Overlaps in API excipient combinations |
Patent families and equivalent patents
The applicant has filed continuations and foreign counterparts, including applications in Europe and Japan, extending protection into key markets. This indicates strategic positioning around specific formulation innovations.
Patent expiration timeline
Assuming the patent grants in early 2023, standard U.S. patent term adjustments apply, with expiry anticipated around 2043, considering potential extensions like patent term adjustment (PTA) for prosecution delays.
Freedom-to-operate considerations
The landscape shows existing patents on controlled-release matrix formulations, but the specific claims on the novel excipient combination and manufacturing process likely provide a freedom-to-operate window for certain APIs and delivery systems not explicitly covered.
Patent strategy and implications
- Innovator advantage: The broad claims on formulation and method enable the patent holder to defend against competitors developing similar delivery systems.
- Potential challenges: Prior art on biodegradable polymer matrices and controlled-release formulations could be cited to narrow or invalidate certain claims during litigation or patent examination.
- Licensing prospects: The patent’s broad scope and strategic filings make it attractive for licensing within the pharmaceutical industry, especially for drugs targeting chronic conditions requiring sustained release.
Regulatory and competitive landscape
- Regulatory implications: The formulation claims align with contemporary FDA guidance on controlled-release drug products. The patent could facilitate expedited review if combined with bioequivalence data.
- Competitive positioning: Patented formulations could block generic development of similar controlled-release systems for the API, providing market exclusivity.
Key Takeaways
- U.S. Patent 11,602,513 protects a specific controlled-release formulation and related manufacturing processes.
- Scope is broad but constrained by specific process steps and ratios, likely to withstand challenges with prior art.
- The patent landscape emphasizes existing controlled-release technologies, but the specific combination and methods in this patent present strategic advantages.
- Licensing or product development should focus on the specific conditions targeted, avoiding overlaps with prior patents in release matrix technology.
FAQs
Q1: How does U.S. Patent 11,602,513 differ from previous controlled-release patents?
It claims a specific combination of API with a unique excipient matrix and manufacturing process, rather than generic controlled-release formulations.
Q2: What is the expected duration of protection for this patent?
Typically, until around 2043, factoring in patent term adjustments and extensions.
Q3: Can this patent prevent others from developing similar delivery systems?
It provides a barrier for formulations using the claimed excipient combinations and manufacturing methods. However, alternative matrices or processes may not be covered.
Q4: Are there similar patents in Europe or Asia?
Yes, the applicant has filed for corresponding patent applications internationally, expanding geographical protection.
Q5: How might patent challenges unfold?
Oppositions or invalidation efforts may reference prior art on controlled-release technology, but the specific formulation claims are likely defensible.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 11,602,513.
[2] Patent Landscape Reports on Controlled-Release Technologies. (2022).
[3] European Patent Office. (2023). Patent family filings related to controlled-release formulations.
